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Abstract
Background: The success of hematopoietic stem cell (HSC) transplantation is dependent on the quality of
the donor HSCs. Some sources of HSCs display reduced engraftment efficiency either because of inadequate
number (e.g., fetal liver and cord blood), or age-related dysfunction (e.g. in older individuals). Therefore, use of
pharmacological compounds to improve functionality of HSCs is a forefront research area in hematology.
Methods: Lineage negative (Lin−) cells isolated from murine bone marrow or sort-purified Lin−Sca-1+c-Kit+CD34−
(LSK-CD34−) were treated with a nitric oxide donor, sodium nitroprusside (SNP). The cells were subjected to various
phenotypic and functional assays.
Results: We found that SNP treatment of Lin− cells leads to an increase in the numbers of LSK-CD34+ cells in them.
Using sort-purified LSK CD34− HSCs, we show that this is related to acquisition of CD34 expression by LSK-CD34−
cells, rather than proliferation of LSK-CD34+ cells. Most importantly, this upregulated expression of CD34 had
age-dependent contrasting effects on HSC functionality. Increased CD34 expression significantly improved the
engraftment of juvenile HSCs (6–8 weeks); in sharp contrast, it reduced the engraftment of adult HSCs (10–12 weeks).
The molecular mechanism behind this phenomenon involved nitric oxide (NO)-mediated differential induction
of various transcription factors involved in commitment with regard to self-renewal in adult and juvenile HSCs,
respectively. Preliminary experiments performed on cord blood-derived and mobilized peripheral blood-derived cells
revealed that NO exerts age-dependent contrasting effects on human HSCs as well.
Conclusions: This study demonstrates novel age-dependent contrasting effects of NO on HSC functionality and
suggests that HSC age may be an important parameter in screening of various compounds for their use in
manipulation of HSCs.
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Background
The success of hematopoietic stem cell (HSC) trans-
plantation is dictated by the quality of the donor HSCs,
and is dependent on their ability to home to the bone
marrow (BM) of recipients, self-renew, and differentiate.
Similarly, the HSCs differentiated from embryonic stem
(ES) cells or induced pluripotent stem (iPS) cells fail to
engraft irradiated hosts [1–3]. Hence, two principal ap-
proaches are taken to improve the engraftment of donor
HSCs; one, therapeutic targeting of the HSC niche [4, 5],
and two, direct treatments of HSCs [6–10].
Nitric oxide (NO), a short-lived free radical, regulates
several aspects of hematopoiesis in a development-
dependent manner. It has been shown to play an
important role in hematopoietic development in the
embryonic stage [11]. Silencing of genes encoding NO
synthase (NOS) blocked HSC development which could
be rescued by treatment with NO donors. NO is also
known to play a critical role in shear stress-induced
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augmentation of hematopoiesis from mouse ES cells
[12].The importance of NO in adult hematopoiesis was
underscored by the finding that mice deficient in NOS3
show reduced hematopoietic recovery and impaired
mobilization of endothelial cells [13, 14]. Conversely,
treatment of adult mice with NOS inhibitors increased
the number of stem cells, suggesting that NO limits
HSC proliferation [15]. In vitro treatment of adult BM
cells with NO donors inhibits erythroid progenitors
while stimulating myeloid progenitors [16, 17]. However,
direct effects of NO donors on HSC functionality were
not examined.
Here we show that treatment of LSK-CD34− HSCs
with NO donors upregulates CD34 expression in them
through a cGMP-independent pathway. Importantly, the
upregulated expression of CD34 was associated with
self-renewal and gain of functionality in the juvenile
HSCs (6–8 weeks), whereas it was associated with
lineage commitment and loss of functionality in the
adult HSCs (10–12 weeks). These data demonstrated
that NO has age-dependent contrasting effects on mur-
ine HSCs. Preliminary experiments performed on cord
blood (CB) and mobilized peripheral blood leukocytes
(MBPL) also showed that NO exerts age-dependent
effects on human HSCs as well.
Our data suggest that NO donors could be used to
improve the engraftment ability of HSCs derived from
younger sources such as ES/iPS cells (embryonic), fetal
liver (fetal), and cord blood (neonatal), but their use in
manipulation of adult HSCs may be avoided.
Methods
Animals
Protocols for animal experiments were approved and were
performed in accordance with the Institutional Animal
Ethical Committee (IAEC) of the National Centre for Cell
Science (NCCS) and the Committee for the Purpose of
Control and Supervision of Experiments on Animals
(CPCSEA) (approval number: EAF/2010/B-151). Through-
out the experiments animals were under the supervision of
trained personnel. C57BL/6 J (CD45.2) and B6.SJL- Ptprca
Pep3b/BoyJ (CD45.1) mice purchased from Jackson
Laboratory (Bar Harbor, ME, USA) were housed and bred
in the institutional experimental animal facility. Mice at
6–8 or 10–12 weeks of age were used in the experiments.
Cell culture and treatments
BM-derived mononuclear cells (MNCs) of Ptprc (CD45.1)
mice were depleted of lineage-positive cells using the
immuno-magnetic technique (Additional file 1: Table S1).
This HSC-enriched lineage-negative fraction, or LSK-CD34
− cells sorted from them, were cultured in Iscove’s modi-
fied Dulbecco’s medium (IMDM; HiMedia, Mumbai,
India) supplemented with 10% Mesen-fetal bovine serum
(FBS) (Invitrogen, California, USA) and mouse-specific
growth factors (IL-3, 5 ng/ml; IL-6, 12.5 ng/ml; and SCF,
12.5 ng/ml; Peprotech, NJ, USA), and treated with sodium
nitroprusside (SNP; Alexis, NY, USA) at various concen-
trations and time intervals as indicated in the results sec-
tion. Likewise, treatment of sorted LSK-CD34− cells with
various pharmacological reagents has been described in
the respective results section. The viability of cells was
>98% as determined by Trypan blue dye exclusion
method.
Isolation of murine lineage-negative cells and sorting of
LSK-CD34− and LSK-CD34+ cells
Murine lineage negative (Lin−) cells were isolated from
the bones of Ptprc (CD45.1) mice. The mice were sacri-
ficed and the hind limbs (femur and tibia) were dissected
out. The bone marrow was flushed into IMDM supple-
mented with 5% FBS, and the MNCs were isolated by
density gradient centrifugation (HiSep™ Hi Media,
Mumbai, India). For the isolation of Lin− cells the MNCs
were first incubated with biotin-labeled anti-mouse
lineage antibody cocktail (Additional file 1: Table S1) pre-
pared from biotin mouse lineage panel (BD Pharmingen,
New Jersey, USA) and then the antibody-bound lineage-
positive cells were depleted using Dynabeads® biotin
binder (Invitrogen, Carlsbad, California, USA).
For sorting of LSK-CD34− and LSK-CD34+ cells, the
MNCs were incubated with antibodies (Additional file 1:
Table S1) against lineage markers, Sca-1, c-Kit, and
CD34. Cells were washed to remove unbound antibodies
and LSK-CD34− and LSK-CD34+ cells were sorted on
FACS ARIA II (Becton Dickinson, New Jersey, USA).
Phenotypic analysis of hematopoietic progenitors
To analyze hematopoietic progenitors, murine lineage nega-
tive (Lin–) cells were isolated from mouse BM by immuno-
magnetic separation as mentioned above. These cells were
then cultured for 3 days with or without SNP. Cells were
harvested and stained with antibodies against Lineage
markers, c-Kit, Sca-1, IL-7R (CD127), and FcR (CD16/32)
(Additional file 1: Table S1). Cells were washed and acquired
on FACS Canto II (Becton Dickinson). Common myeloid
populations (CMP; Lin−c-Kit+Sca-1−FcRlowCD34+) and
common lymphoid population (CLP; Lin−IL-7R+c-Kit low-
Sca-1low) were analyzed as per the gating strategy shown
in Additional file 2 (Figure S5).
Human samples
CB and MBPL samples were collected from local hospi-
tals after obtaining informed consent with the compli-
ance of the institutional review board (Institutional
ethical committee (IEC) and Institutional Committee for
Stem Cell Research (IC-SCR) of the NCCS) according to
the Declaration of Helsinki. Consenting procedures were
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also approved by the IC-SCR of the NCCS. MNCs were
isolated from CB and MBPL by density gradient separ-
ation using HiSep (HiMedia). MNCs (5 × 106) were sus-
pended in IMDM supplemented with 10% FBS and
human-specific growth factors (IL-3, 5 ng/m; IL-6,
12.5 ng/ml; and SCF, 12.5 ng/ml; Peprotech, NJ, USA).
They were treated with SNP (100 μM) for 3 days and
analyzed on a flow cytometer.
Flow cytometric analysis
The immuno-stained cells were acquired on FACS
Canto II ((Becton Dickinson). Doublets were excluded
by FSC-H × FSC-W and SSC-H × SSC-W. Appropriate
isotype control antibodies were used for each antibody.
Single flurochrome-stained cells were used for com-
pensation. All flow-qualified antibodies were purchased
from BD Biosciences (San Jose, CA, USA) or eBioscience
(San Diego, CA, USA), unless mentioned otherwise.
Specific clones of various antibodies used are listed in
Additional file 1 (Table S1). Data were analyzed using
BD FACS DIVA as well as BD Flow Jo software.
EdU labeling assay
To analyze the frequency of proliferating LSK-CD34− and
LSK-CD34+ cells, EdU (5-ethynyl-2’-deoxyuridine) label-
ing assay was performed using Click-iT® EdU Alexa Fluor®
647 Flow Cytometry Assay Kit (Invitrogen, Carlsbad, Cali-
fornia, USA) as per the manufacturer’s instructions.
Briefly, lineage-negative hematopoietic cells were treated
with SNP (100 μM) for 3 days. Cells without the addition
of SNP were used as controls. Cells were pulsed with EdU
for 2 h and then harvested. The cells were fixed and
permeabilized using the permeabilization buffer provided
in the kit, and EdU reaction cocktail was added. The cells
were stained using antibodies to Sca-1, c-Kit, and
lineage markers, and acquired on a flow cytometer. The
frequency of EdU+ cells in LSK-CD34− and LSK-CD34+
HSCs was determined using BD FACS DIVA software.
Nitrite estimation
To estimate nitrite production, the conditioned media
from various cultures were collected, spun to remove
debris, and the amounts of nitrites formed were esti-
mated using Griess reagent. Conditioned media was
mixed with an equal amount of 1% Griess reagent (1%
sulphanilamide in 5% phosphoric acid, 0.1% naphthyl
ethylene diamine dihydrochloride) and incubated for
10 min at room temperature. OD540 was measured using
a spectrophotometer. A standard graph was prepared
using various concentrations of NaNO2.
Gene expression analysis
Cells were lysed in lysis buffer, and mRNA was isolated
using the Dynabeads® mRNA DIRECT™ Purification Kit
(Invitrogen) according to the manufacturer’s instruc-
tions. C-DNA was prepared using Superscript IIIRT en-
zyme (Invitrogen). Samples without reverse transcriptase
were used to detect genomic DNA contamination.
Primers were designed using Primer-3 software V0.4.0
(http://primer3.ut.ee). Primer sequences are listed in
Additional file 1 (Table S2). Quantitative RT-PCRs were
performed using the Platinum® SYBR® Green (DSS Takara
Bio India Pvt. Ltd., New Delhi, India) and analyzed on the
ABI 7500 fast system (Applied Biosystems, Foster City,
CA, USA). Gene expression was normalized with the β-
actin. Relative gene expression was calculated as 2ΔCt.
Gene silencing
siRNA against c-Myb was synthesized in vitro using a
Silencer® siRNA Cocktail Kit (RNase III) (Invitrogen,
California, USA) as per the manufacturer’s instruction.
Briefly, using c-Myb-specific primers having a T7-pro-
moter leader (8 nucleotides) sequence (Additional file
1: Table S3), a c-myb-specific stretch of cDNA was ampli-
fied from LSK-CD34− cells. Amplicons were again ampli-
fied using T7 promoter primer. The sense and antisense
siRNA templates were transcribed by T7 RNA polymerase
and the resulting RNA transcripts were hybridized to cre-
ate dsRNA. RNAse III was used to produce siRNAs (12–
30 base pairs long) which were further purified. The
resulting c-myb siRNA or c-jun siRNA (Santa Cruz
Biotech, TX, USA) were transfected into sort-purified
LSK-CD34− cells using Dharmafect reagent (Thermo
Scientific, MA, USA) in a 1:1 ratio. Mock transfected cells
were used as controls. Efficiency of silencing of these
SiRNA was determined by qRT-PCR using c-Myb-
and c-Jun-specific primers. Cells were incubated for
12–18 h and then treated with SNP for 12 h. Levels
of c-Jun, c-Myb, and Cd34 mRNA were analyzed by
qRT-PCR.
In vivo transplantation assays
The CD45.1 and CD45.2 congenic chimera mouse
model was used. For primary transplantation, lineage-
depleted HSCs (CD45.1) from various cultures were
harvested and 1 × 106 cells admixed with 1 × 105 freshly
isolated CD45.2 cells were intravenously infused into
lethally irradiated (9.5 Gy, two split doses given 4 h apart
using γ-radiation from a Co60 source) recipients (CD45.2).
The level of chimerism in the peripheral blood of the
recipients was assessed after 4 and 16 weeks of trans-
plantation. Engraftment by donor HSCs (LSK-CD34+ and
LSK-CD34−) in the bone marrow of recipients was ana-
lyzed at 16 weeks post-transplant.
For secondary transplantation, the engrafted donor
cells were sorted from the MNCs isolated from the tibia
and femur bones of the primary recipients, and 5 × 105
sorted donor cells were infused into irradiated secondary
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recipients (CD45.2). The donor cell chimerism in the per-
ipheral blood of secondary recipients was analyzed 4 and
16 weeks post-transplantation. Engraftment of donor
HSCs (LSK-CD34+ and LSK-CD34−) in the bone marrow
of recipients was analyzed at 16 weeks post-transplant.
Statistical analyses
Results were analyzed by one-way repeated-measures
analysis of variance using the software Sigma Stat
(Jandel Scientific Corporation, San Rafael, CA, USA) for
all the experiments. P ≤ 0.05 was considered significant.
Results are expressed as mean value ± SEM.
Results
NO donors increase the frequency of LSK-CD34+ HSCs
To analyze the effect of NO on murine HSCs, lineage-
negative (Lin−) cells isolated from murine bone marrow
(6–8 weeks old) were treated with 100 μM of SNP for
3 days. At concentrations up to 200 μM, SNP did not
show any cytotoxicity (data not shown). The total number
of hematopoietic cells significantly increased after treat-
ment with SNP, but the number of Lin− cells decreased
(Fig. 1a; Additional file 3: Figure S1a). Flow cytometry ana-
lysis of the output cells (Additional files 1 and 3: Table S1
and Figure S1b) showed that SNP treatment significantly
reduced the frequencies and total numbers of LSK-HSCs
(Fig. 1b and d; Additional file 3: Figure S1a and c). A con-
comitant increase in the frequency of LSK-CD34+ HSCs
and a decrease in the frequency of LSK-CD34− HSCs were
seen (Fig. 1c). The ratio of CD34+:34− LSK-HSC was
reversed as compared to the control cells and the input
populations (Additional file 3: Figure S1d). The absolute
number of LSK-CD34− cells decreased significantly, but
the absolute numbers of LSK-CD34+ cells did not change
appreciably (Fig. 1d), suggesting that the increase in LSK-
CD34+ cells was perhaps occurring at the expense of LSK-
CD34− cells.
To address this issue, SNP-treated or untreated Lin−
cells were subjected to EdU-labeling assay [18]. We
found that the percentage of EdU+ cells among the LSK-
CD34− HSCs was significantly higher in SNP-treated
cells, as compared to the control cells, but the percent-
age of EdU+ LSK-CD34+ cells was similar in both sets
(Fig. 1e; Additional file 3: Figure S1e). These data show
that the LSK-CD34− HSCs proliferate in response to
NO. This led us to hypothesize that the increase in the
LSK-CD34+ population in response to NO is likely to be
related to the acquisition of CD34 expression by LSK-
CD34− cells, rather than expansion of LSK-CD34+ cells.
NO donors upregulate CD34 expression in
LSK-CD34− HSCs
To test the hypothesis that the NO-mediated increase in
LSK-CD34+ cells is due to the acquisition of CD34
expression by CD34− HSCs, sort-purified LSK-CD34−
HSCs were exposed to various concentrations of SNP
for 12 h and analyzed on a flow cytometer. We found
that SNP had no effect on the frequency of LSK-CD34+
cells at concentrations up to 50 μM (Fig. 2a). The fre-
quency started rising at a concentration of 100 μM, but
the most significant increase in the frequency of LSK-
CD34+ cells and the highest mean fluorescence intensity
(MFI) of CD34 were seen at 200 μM SNP (Fig. 2a, b and c).
The treated cells were also subjected to qRT-PCR analysis
to examine whether the upregulation of CD34 was also
Fig. 1 Sodium nitroprusside (SNP) increases the frequency of LSK-CD34
+ hematopoietic stem cells (HSCs). Murine lineage-negative (Lin−) bone
marrow cells were exposed to 100 μM of SNP for 3 days and the output
cells were enumerated and analyzed by flow cytometry. a Absolute
numbers of hematopoietic cells and lineage-negative cells generated in
the cultures are depicted. b Frequency of LSK HSCs in the output cells.
c Frequency of CD34− and CD34+ HSCs in the gated LSK population is
illustrated. d Graph shows absolute numbers of LSK, LSK-CD34−, and
LSK-CD34+ HSCs. e The frequency of EdU+ cells in the gated LSK-CD34−
and LSK-CD34+ population is illustrated. The data are represented as
mean ± SEM. N= 3. *p ≤ 0.05, **p ≤ 0.01, ***p ≤ 0.001. Also see Additional
file 3 (Figure S1). NS not significant
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Fig. 2 Sodium nitroprusside (SNP) upregulates surface expression and mRNA of CD34 in the LSK-CD34− HSCs. (a-e) Sort-purified LSK-CD34− HSCs
were exposed to various concentrations of SNP for 12 h. The cells were analyzed for the surface expression of CD34 by flow cytometry and for
Cd34 mRNA expression by qRT-PCR. a Frequency of LSK-CD34+ cells formed in response to various concentrations of SNP. b, c The graph and the
flow panel show mean fluorescence intensity (MFI) of CD34 fluorescence. d Dose-dependent effect of SNP on Cd34-specific mRNA levels in the
treated cells. e The amounts of nitrites formed in the conditioned medium of cells. (f-j) Sort-purified LSK-CD34− cells were exposed to 200 μM
SNP for various time periods. The cells were analyzed for the surface expression of CD34 by flow cytometry. f The time-dependent increase in the
frequency of LSK-CD34+ cells in response to SNP treatment is shown. g, h The graph and the flow panel show MFI of CD34 fluorescence. i
Amounts of nitrites formed in the conditioned medium of the cells. j Expression of Cd34-specific mRNA in the cells treated with 200 μM SNP
for 12 h. The data are represented as mean ± SEM. N = 3. **p ≤ 0.01, ***p ≤ 0.001. Also see Additional file 4 (Figure S2)
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happening at the transcriptional level (Additional file 1:
Table S2). We found that levels of Cd34 mRNA also
remained steady up to 50 μM SNP, but increased signifi-
cantly with 100 and 200 μM SNP (Fig. 2d). This increase
in the frequency of CD34+ cells and increase in Cd34
mRNA closely matched with the increase in the concen-
tration of nitrites formed in the conditioned medium,
showing that the release of NO was necessary for the ob-
served effects (Fig. 2e).
SNP was then used to treat LSK-CD34− HSCs at a
concentration of 200 μM for various time periods to
determine the time-dependent effect of NO on CD34
expression. The frequency of LSK-CD34+ cells and their
MFI increased steadily with an increase in the duration
of SNP treatment, and at 12 h this increase became
highly significant (Fig. 2f, g and h). This increase closely
correlated with the increase in the nitrite concentration
in their conditioned medium (Fig. 2i). Based on these
data, the LSK-CD34− cells were treated with 200 μM
SNP for 12 h and were subjected to qRT-PCR analyses.
We found a significant upregulation of Cd34-spcific
mRNA expression in the treated cells (Fig. 2j).
We also examined the effect of SNP on sort-purified
LSK-CD34+ (ST-HSCs) cells and found that SNP also
upregulated the surface expression and MFI of CD34 in
these cells (Additional file 4: Figure S2a, b and c). An in-
crease in the Cd34-specific mRNA was also seen in these
cells with a treatment of 200 μM SNP for 12 h
(Additional file 4: Figure S2d).
Collectively, these data confirmed that LSK-CD34−
HSCs are the primary cellular targets of NO action with
respect to CD34 expression. All further experiments
were performed on sorted LSK-CD34− cells treated with
200 μM SNP for 12 h, unless stated otherwise.
Pure NO is required for the induction of CD34 mRNA and
surface expression
It is known that pharmacological agents such as SNP
may also generate by-products other than NO. To deter-
mine whether NO was involved in the upregulation of
surface expression of CD34, the sorted LSK-CD34− cells
were incubated with SNP in the presence of 100 μM
c-PTIO (2-(4-carboxyphenyl)-4,4,5,5-tetramethylimidazo-
line-1-oxyl-3-oxide), which is a specific scavenger of NO.
We found that in the presence of c-PTIO, the SNP-
mediated increase in the surface expression and MFI of
CD34 was significantly reduced (Fig. 3a, b and c). Simi-
larly, the SNP-mediated increase in Cd34 mRNA levels
was also prevented by the addition of c-PTIO (Fig. 3d).
These data point towards a direct role of NO in the upreg-
ulation of surface expression of CD34 in the HSCs.
Since pharmacological agents may have off-target
effects, the sorted LSK-CD34− cells were exposed to two
other NO donors, namely 3-morpholinosydnonimine
(SIN-1) and diethylenetriamine/nitric oxide adduct
(DETA NONOate; NOC-18) for 12 h. We found that
both compounds increased the surface expression and
MFI of CD34 in a dose-dependent manner (Additional
file 5: Figure S3a, b, c and d), clearly establishing that
CD34 is indeed a direct target of NO action.
Nitric oxide-mediated upregulation of CD34 is dependent
on de novo mRNA and protein synthesis
To elucidate whether the induction of CD34 expression
in response to NO required de novo synthesis of mRNA,
the sort-purified LSK-CD34− HSCs were treated with ac-
tinomycin D (ActD; 5 μg/ml) and SNP or with ActD
alone for 12 h and were subjected to qRT-PCR analysis.
As shown in Fig. 4a, the SNP-mediated increase in
Cd34-specific mRNA in the LSK CD34− cells was inhib-
ited in the presence of ActD, indicating the requirement
of a de novo mRNA synthesis for the process. A similar
effect was also seen at the protein level (Fig. 4b and c).
These data reveal that NO-mediated upregulation of
CD34 requires de novo mRNA synthesis.
We then examined whether NO-mediated upregulation
of Cd34 needs de novo protein synthesis. The sort-
purified LSK-CD34− HSCs were incubated for 12 h with
SNP in the presence or absence of puromycin (20 μg/ml),
an inhibitor of translation initiation. We found that puro-
mycin inhibited the NO-mediated upregulation of Cd34
mRNA (Fig. 4d), showing that NO-mediated upregulation
of Cd34 requires de novo protein synthesis as well.
NO-induced CD34 expression is independent of cGMP,
but involves S-nitrosylation of proteins
NO is known to mediate its effects through the activa-
tion of sGC, which leads to an increase in cGMP [19].
To determine whether the SNP-induced increase in
CD34 expression was dependent on cGMP, the effect of
the membrane-permeable cGMP analogue, 8-Cl-cGMP,
on membrane expression of CD34 was examined. After
exposure of sorted LSK-CD34− cells to 8-Cl-cGMP
(100 μM) for 12 h, CD34 surface expression and its MFI
remained unaltered (Fig. 5a, b and c). Next, we exam-
ined the effect of Rp-cGMP, a specific inhibitor of
cGMP-dependent protein kinase. Sorted LSK-CD34−
cells were pre-incubated with 100 μM Rp-cGMP for
30 min before the addition of SNP. Addition of Rp-cGMP
did not alter the SNP-mediated upregulation of CD34 or
its MFI (Fig. 5d, e and f). Expression of Vegf-a-specific
mRNA in BMSCs directly treated with 8-Cl-cGMP and
BMSCs treated with SNP in the presence of Rp-cGMP
was used as a positive control to demonstrate the activity
of Rp-cGMP and 8-Cl-cGMP, respectively (Additional
file 5: Figure S3e–f ). Collectively, these data show that
NO-mediated upregulation of CD34 is independent of
intracellular cGMP.
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NO can alter a wide variety of cellular functions by S-
nitrosylation of proteins [20]. To determine whether the
induction of CD34 expression by NO involves such a
mechanism, sorted LSK-CD34− cells were incubated for
30 min with 200 μM DTT before the addition of SNP.
We found that the SNP-mediated increase in surface
expression and MFI of CD34 was significantly reduced
by the addition of DTT (Fig. 5 g, h and i), suggesting
that NO exerts its effect on CD34 by S-nitrosylation of
proteins.
NO upregulates CD34 gene expression via c-Myb and
c-Jun
Transcription factors (TFs) such as c-Myb and c-Jun are
known to play an important role in stem cell biology
and are also known to be regulated by NO in various cell
systems [21–23]. First, we determined whether SNP has
any effect on their expression in the HSCs. The LSK-
CD34− cells showed a basal level expression of both
these TFs, and SNP treatment upregulated the ex-
pression of c-Jun in LSK-CD34− HSCs, but did not affect
c-Myb expression (Fig. 6a and c). Aliquots of LSK-CD34−
HSCs were transfected separately with c-Jun- and c-Myb-
specific siRNA (Additional file 1: Table S3) 18 h before the
treatment with SNP, and were subjected to qRT-PCR ana-
lyses. We found that the NO-mediated upregulation of
Cd34 mRNA was significantly affected in the cells trans-
fected with siRNA to c-Jun and c-Myb (Fig. 6b and d),
showing that the process involved both TFs. The effect of
silencing of c-Jun was more striking, as compared to that
seen with c-Myb silencing, indicating that c-Jun plays a
more crucial role in the process.
NO-induced CD34 expression has age-dependent
implications in the functionality of HSCs
CD34+ HSCs from juvenile mice (6 weeks old) have
been shown to possess engraftment ability [24, 25]. We
therefore determined the consequences of upregulated
CD34 expression in the HSCs on their in vivo function-
ality (Additional file 6: Figure S4a). The Lin− cells (6–8
weeks old) were treated with SNP for 3 days and infused
into irradiated recipients (8–10 weeks old). At 4 weeks
post-transplant, the level of chimerism in the peripheral
blood (PB) of the recipients was comparable in the
Fig. 3 Addition of the nitric oxide scavenger c-PTIO abolishes sodium nitroprusside (SNP)-mediated upregulation of CD34 expression. Sort-purified
LSK-CD34− cells were exposed to 200 μM SNP for 12 h with or without the addition of 100 μM c-PTIO. The cells were analyzed for CD34 surface
expression by flow cytometry, and Cd34-specific mRNA was quantified by qRT-PCR. a Graph shows frequency of LSK-CD34+ cells formed in cultures.
b, c The graph and the flow panel show the mean fluorescence intensity (MFI) of CD34 fluorescence. d Relative expression of Cd34-specific mRNA in
the treated cells. The data are represented as mean ± SEM. N = 3. ***p ≤ 0.001. Also see Additional file 5 (Figure S3). NS not significant
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control and SNP-treated sets (Fig. 7a; Additional file 6:
Figure S4b). However, at 16 weeks a significant increase
in the level of chimerism was observed with the SNP-
treated cells as compared to controls (Fig. 7b). No
lineage bias was seen in the regenerated blood cells at
4 weeks post-transplant in either set (Additional file 6:
Figure S4c). At 16 weeks post-transplant, the percentage
of myeloid cells was significantly lower in the SNP-
treated set as compared to the control set, but the per-
centage of B and T cells was similar in both (Additional
file 6: Figure S4d). Surprisingly, analysis of BM per-
formed at 16 weeks post-transplant showed that the per-
centage of total donor cells and LSK-CD34− HSCs were
not significantly different between the two groups (Fig. 7c
and d). The engrafted donor cells from the bone marrow
of primary recipients were sorted and infused into irradi-
ated secondary recipients to assess their long-term func-
tionality. We found that, in secondary hosts, the cells
sorted from primary recipients that had received SNP-
treated cells showed significantly higher engraftment at
both 4 and 16 weeks post-transplant (Fig. 7e and f).
These data suggest that the NO-mediated increase in
CD34 expression is perhaps a reflection of self-renewal
in juvenile HSCs.
Previous reports have shown that HSCs collected from
adult mice (12 weeks) treated with NO donors possess
reduced engraftment ability, suggesting that NO has a
detrimental effect on HSC functionality [26]. In sharp
contrast, we found that SNP treatment of juvenile HSCs
boosted their engraftment ability. To determine the ef-
fect of SNP on the engraftment ability of adult HSCs,
adult Lin− cells (10–12 weeks) treated with SNP for
3 days were infused into irradiated hosts and their en-
graftment levels were monitored at 4 and 16 weeks post-
transplant. We found that the level of chimerism at
4 weeks post-transplant was comparable in both control
and SNP-treated sets, but at 16 weeks post-transplant
the SNP-treated adult cells showed significantly lower
chimerism in the PB of the recipients (Additional file 3:
Figure S5a and b). No lineage bias was observed in the
Fig. 4 Upregulation of CD34 expression by sodium nitroprusside (SNP) is dependent on de novo mRNA and protein synthesis. Sort-purified LSK-CD34−
cells were treated with 200 μM SNP for 12 h with or without the addition of 5 μg/ml actinomycin D (Act D). The cells were subjected to qRT-PCR
and flow cytometry analyses. a Relative expression of Cd34-specific mRNA in the treated cells. b The frequency of LSK-CD34+ cells formed in the
cultures. c Effect of ActD on the mean fluorescence intensity (MFI) of CD34 fluorescence is depicted. d Sort-purified LSK-CD34− cells were treated with
200 μM SNP for 12 h with or without the addition of pruromycin (20 μg/ml). The cells were subjected to qRT-PCR analyses. Relative expression of
Cd34-specific mRNA in the treated cells is illustrated. The data are represented as mean ± SEM. N = 3. ***p ≤ 0.001. NS not significant
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regenerated blood cells formed in the PB of the recipients
at both 4 and 16 weeks post-transplant showing that al-
though the overall engraftment ability of SNP-treated cells
was compromised, the engrafted HSCs could give rise to
multi-lineage hematopoiesis under the influence of a local
micro-environment (Additional file 3: Figure S5c and d).
BM analysis performed at 16 weeks also showed that the
number of LSK-CD34− LT-HSCs was significantly lower
in the SNP-treated set, although the total number of
engrafted donor cells was comparable in both control and
SNP-treated sets (Additional file 3: Figure S5e and f).
These data clearly demonstrated that NO has an age-
dependent effect on HSC functionality.
NO upregulates CXCR4 surface expression in both
juvenile and adult HSCs
The lack of difference in the engraftment levels shown
by control and SNP-treated cells in the BM of recipients
Fig. 5 NO-mediated CD34 expression is independent of the activation of the cGMP signaling pathway, but depends on S-nitrosylation of proteins.
Sort-purified LSK-CD34− cells were exposed to 200 μM sodium nitroprusside (SNP) or 100 μM 8-Cl-cGMP, a membrane-permeable cGMP analogue,
for 12 h. The cells were analyzed by flow cytometry. a The frequency of LSK-CD34+ cells generated in the culture is graphically illustrated. b, c
The graph and the flow panel show mean fluorescence intensity (MFI) of CD34 fluorescence. Sort-purified CD34− cells were exposed to 200 μM
SNP in the presence or absence of 100 μM Rp-cGMP, a specific inhibitor of cGMP-dependent protein kinase, for 12 h. The cells were subjected to
flow cytometry analysis. d The frequency of LSK-CD34+ cells generated in the cultures is illustrated. e, f The graph and the flow panel show the
MFI of CD34 fluorescence. Sort-purified CD34− cells were exposed to 200 μM SNP in the presence or absence of 200 μM DTT for 12 h. g The
frequency of LSK-CD34+ cells generated in the cultures is depicted. h, i The graph and the flow panel show the MFI of CD34 fluorescence. The
data are represented as mean ± SEM. N = 3. ***p ≤ 0.001. Also see Additional file 5 (Figure S3). NS not significant
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as compared to the significant differences in percentage
chimerism in the PB in recipients prompted us to exam-
ine the reason behind this discrepancy. CXCR4 plays an
important role in the retention of HSCs in the BM mi-
lieu. Furthermore, NO has been shown to induce
CXCR4 expression in human CD34+ HSCs [27]. We
therefore examined whether NO also increases CXCR4
expression in murine HSCs. We found that both juvenile
and adult LSK-CD34− and LSK-CD34+ HSCs showed an
enhanced mRNA and surface expression of CXCR4 in
response to NO (Additional file 7: Figure S6a and b).
These data show that perhaps this NO-mediated en-
hanced CXCR4 expression enabled the SNP-treated
adult as well as juvenile HSCs to home and accumulate
in the BM of recipients at a similar level. These data
demonstrate that reduced chimerism exhibited by SNP-
treated adult HSCs in the PB of recipients was not
related to loss of CXCR4 expression, but was perhaps
related to their inability to form blood cells as effectively
as SNP-treated juvenile HSCs, suggesting loss of self-
renewal in them.
Molecular mechanism behind age-dependent contrasting
effect of NO on HSC functionality involves differential
expression of transcription factors
The differential effect of NO on the HSC functionality
prompted us to examine whether this was related to
differential expression of self-renewal with regard to
commitment-related TFs in the HSCs in an age-dependent
manner. To examine this, the sorted LSK-CD34− cells col-
lected from 6–8 weeks old (juvenile HSCs) and 10–12
weeks old (adult HSCs) mice were treated with SNP for
3 days and were analyzed by qRT-PCR. The adult HSCs
showed very high expression of c-Myc and PU.1 as
compared to the juvenile HSCs (Fig. 7 g). The levels of
Ikzf3 (Ikaros) was similar in both the sets. Overexpression
of c-Myc leads to a loss of self-renewal ability of the HSCs
at the expense of differentiation [28] and PU.1 is a known
myeloid commitment marker [29]. Consistent with these
results, the frequency of common myeloid progenitors
(CMP) in the output population of SNP-treated adult Lin−
cells was significantly higher as compared to that in SNP-
treated juvenile Lin− cells. The frequency of common
Fig. 6 NO-mediated upregulation of CD34 involves c-Myb and c-Jun. Sort-purified LSK-CD34− cells were transfected with siRNA to c-Jun and
c-Myb. Mock transfected cells were used as controls. After 18 h post-transfection, the cells were exposed to 200 μM sodium nitroprusside (SNP) for 12 h
and then subjected to qRT-PCR analyses. Relative expression of c-Jun-specific mRNA (a) and Cd34-specific mRNA (b) in the cells transfected with
c-Jun-specific siRNA, with or without the treatment with SNP, is depicted. Relative expression of c-Myb-specific mRNA (c) and Cd34-specific mRNA (d) in
the cells transfected with c-Myb-specific siRNA, with or without the treatment with SNP, is depicted. ***p ≤ 0.001. NS not significant
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lymphoid progenitor (CLP) was similar in both the sets
(Additional file 7: Figure S6c and d). Interestingly, the level
of Cd34 was significantly higher in the adult HSCs as com-
pared to the juvenile HSCs (Fig. 7 g). These data show that
NO induces a commitment program in the adult HSCs but
not in the juvenile HSCs.
We then decided to examine whether such differential
regulation was also seen with respect to other TFs. We
short-listed the TFs that bind to the CD34 promoter
(TF-bind software) and are regulated by NO in other ex-
perimental systems. We then selected the ones that are
relevant in the context of hematopoiesis. The sorted
LSK-CD34− cells treated or not with SNP for 12 h were
subjected to qRT-PCR analyses and the expression of se-
lected genes was quantified. The relative levels of Cd34
were also assessed. As observed in the earlier experi-
ment, the SNP-mediated increase in Cd34 expression in
adult HSCs was much higher as compared to that in
juvenile HSCs (Fig. 7 h). Also, the genes related to self-
renewal such as Yy1, Chop1, and Runx1 [30–32] were
significantly upregulated in juvenile HSCs as compared
to the adult HSCs. Sp1 is known to positively regulate
the CD34 promoter [33]. Surprisingly, its expression was
higher in juvenile HSCs as compared to the adult HSCs.
Since Cd34 expression was significantly lower in these
cells, it appears that the effect of Sp1was countered by
some unknown mechanisms. Other genes such as Nfya,
Atf1, Vbp1 and c-Myb [34–38] were not affected by NO
in either cells (Additional file 7: Figure S6e). NO upregu-
lated c-Jun expression at comparable levels in both
juvenile and adult HSCs. The level of Trp53 (p53) [39]
in SNP-treated adult HSCs was significantly lower as
compared to that seen in SNP-treated juvenile HSCs.
Collectively, these data show that the age-dependent
contrasting effect of NO on HSC functionality is due to
induction of a self-renewal program in juvenile HSCs
and a commitment process in adult HSCs.
NO also exerts age-dependent effects on human HSCs
To examine whether NO also exerts age-dependent ef-
fects on the human HSCs, we performed preliminary
experiments with CB- and MBPL-derived cells to obtain
a proof of principle. CB- and MBPL-derived MNCs were
treated with SNP (100 μM) for 3 days and the output
cells were subjected to qRT-PCR and flow cytometry
analyses. SNP treatment resulted in a significant increase
in CD34-specific mRNA in both juvenile and adult cells
(Additional file 8: Figure S7b). The increase in CD34
mRNA in adult cells was strikingly high. Flow analysis
revealed that the frequency of CD34+38− HSCs in-
creased significantly in SNP-treated CB cells (Additional
file 8: Figure S7a and c), but decreased significantly in
SNP-treated MPBL cells. A similar result was also ob-
tained when the fold-change in the HSC numbers over
their input was determined (Additional file 8: Figure S7d).
Since human CB- or BM-derived CD34+38− HSCs are
known to have engraftment capacity [40–42], our data
show that treatment of CB cells, but not of adult cells,
leads to a significant increase in HSCs having en-
graftment potential in them. These preliminary data
suggest that NO has an age-dependent effect on CD34
surface expression, and perhaps also functionality, of
human HSCs as well. This aspect needs to be studied
in greater detail.
Discussion
Success of transplantation critically depends on the
quality and functionality of donor HSCs. Therefore, use
of pharmacological agents to improve engraftment of
donor HSCs is being aggressively pursued. In the present
study, we examined the effect of NO donors on the en-
graftment ability of murine HSCs. We also elucidated
the molecular mechanisms involved in the process. Here,
we show for the first time that NO induces CD34 ex-
pression in LSK-CD34− HSCs and this has a contrasting
age-dependent effect on their functionality (Fig. 8).
In a murine system, CD34 antigen expression is consid-
ered as a marker of short-term engrafting HSCs (ST-HSCs).
However, previous reports have demonstrated that the ex-
pression of CD34 on murine HSCs is context-dependent,
and has two implications: it could either be an indication
of progressive commitment and differentiation giving rise
(See figure on previous page.)
Fig. 7 NO-induced CD34 expression has contrasting age-dependent effects on the HSC functionality. Lin− cells isolated from juvenile mice
(6–8 weeks; CD45.1) were treated or not with 200 μM sodium nitroprusside (SNP) for 3 days and infused into irradiated recipients (8–10 weeks;
CD45.2); 7–8 mice were used per group. The level of engraftment was analyzed by flow cytometry analysis of peripheral blood (PB) and bone
marrow (BM). Percentage chimerism by the donor cells in PB of recipients at 4 weeks (a) and 16 weeks (b) post-transplant is depicted. Percentage
engraftment of total donor cells (c) and LSK CD34− LT-HSCs (d) in the BM of recipients is illustrated. The engrafted donor cells were sorted from
the bone marrow of primary recipients and infused into irradiated secondary recipients. The percentage chimerism by these primary engrafted
donor cells was analyzed by flow cytometry in the PB of secondary recipients. Percentage chimerism produced by the primary engrafted cells in
the PB of secondary recipients at 4 weeks (e) and 16 weeks (f) post-transplant is shown; 4–5 secondary recipients were used per group. Sort-purified
LSK-CD34− cells from juvenile (6–8 weeks) and adult (10–12 weeks) mice were treated with 200 μM SNP for 3 days (g) or 12 h (h), and the cells were
subjected to qRT-PCR analyses. Relative expression of Cd34 and various transcription factors is illustrated (means ± SEM; N= 3). *p ≤ 0.05, **p ≤ 0.01,
***p ≤ 0.001, between control and SNP-treated sets; ###p ≤ 0.001, SNP-treated juvenile versus SNP-treated adult HSCs. Also see Additional file 6 (Figure S4).
NS not significant
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to ST-HSCs or it could indicate an activation status of LT-
HSCs, as shown in 5-fluorouracil-treated mice [43]. It has
also been shown that CD34+ HSCs collected from young
mice (6–8 weeks old; juvenile HSCs) possess engraftment
capacity, but the CD34− do not, while in adult mice
(>10 weeks old; adult HSCs) the situation is reversed [24].
These data show that CD34 expression has age- as well as
context-dependent implications in murine hematopoiesis.
In our study, we found that SNP-treated juvenile HSCs en-
graft more efficiently, whereas their adult counterparts do
not. Thus, our data provide direct evidence for the context-
dependent role of CD34 in functionality of murine HSCs.
In vitro exposure of murine BM cells (12 weeks old) to
NO donors has been reported to induce myeloid com-
mitment of HSCs. Similarly, treatment of adult mice
with NO donors resulted in expansion of HSCs in their
bone marrow, but these HSCs lost their long-term
engraftment capacity [26]. Although these results were
suggestive of an increase in ST-HSCs, whether LSK-
CD34− LT-HSCs acquired CD34 expression in response
to NO and contributed to the ST-HSC population, or
whether LSK-CD34+ cells themselves proliferated in
response to NO, was not investigated. Also, previous
studies did not distinguish between the effects of NO on
juvenile as compared to adult HSCs. Such a distinction
is important since CD34 expression has been shown to
have development-specific implications in the function-
ality of murine HSCs [24].
In the present study, we identified murine CD34 and
LSK-CD34− cells as the molecular and cellular targets,
respectively, of NO signaling. We demonstrated that NO
induces CD34 surface expression and Cd34 mRNA
expression in LSK-CD34− cells in a time- and dose-
dependent manner. This was also supported by a strong
correlation between the upregulation of CD34 and the
nitrite concentrations in the medium (an indirect
measure of NO). These data clearly establish that the
NO-mediated increase in LSK-CD34+ cells is related to
acquisition of CD34 expression by the LSK-CD34−
HSCs, rather than proliferation of LSK-CD34+ HSCs.
Very few reports describe the mechanisms involved in
the regulation of CD34 expression in murine HSCs. The
transcription start sites of both murine and human
CD34 genes contain consensus binding sites for several
transcription factors, three of which, myb, ets and mzf-1,
have been shown to affect CD34 expression [44–46].
Sp1 has been shown to regulate murine CD34 at the
transcriptional level [33]. To the best of our knowledge,
ours is the first report showing that NO regulates CD34
expression in murine HSCs at both the transcriptional
and the translational levels.
NO is known to regulate several TFs [47], including
c-Myb and c-Jun. Both these TFs play an important role
in HSC proliferation and are also known to regulate CD34
expression in various cell systems [37, 48, 49]. Using
siRNA-mediated gene silencing, we demonstrated that the
NO-mediated upregulation of CD34 is dependent on
c-Myb as well as c-Jun. Silencing of c-Jun had a stronger
effect on NO-mediated CD34 expression in the LSK
CD34− HSCs, as compared to silencing of c-Myb, suggest-
ing that c-Jun plays a crucial role in the process. The
milder effects seen with silencing of c-Myb are consistent
with the work published by Krause et al. [50]. Upregula-
tion of mitochondrial biogenesis has been shown to paral-
lel upregulation of CD34 in murine HSCs [51]. Whether
NO upregulates mitochondrial biogenesis in the murine
HSCs remains to be seen.
The most important finding in this study was that the
NO-mediated upregulation of CD34 in juvenile HSCs
(6–8 weeks) boosted their engraftment capacity. In sharp
Fig. 8 Graphical summary. NO nitric oxide
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contrast, such an upregulation of CD34 in the adult
HSCs (10–12 weeks) significantly reduced their engraft-
ment capacity. These differences in the engraftment cap-
acities of juvenile and adult CD34+ HSCs are similar to
previous reports showing that CD34+ HSCs from juven-
ile mice, but not from adult mice, possess engraftment
capacity [24, 25]. High levels of c-Myc are known to
compromise the self-renewal ability of HSCs [28].We
found that the NO-mediated upregulation of CD34 was
accompanied by a strong upregulation of c-Myc in adult
HSCs, but not in juvenile HSCs. Similarly, the expres-
sion of Pu.1, a myeloid commitment marker, was highly
upregulated only in the adult HSCs. These data indicate
that NO-induced CD34 expression is accompanied by an
induction of the differentiation program in adult HSCs.
The contrasting functionality observed in juvenile com-
pared to adult HSCs could also be correlated with the dif-
ferential regulation of some important TFs by NO in the
two types of HSCs. The expression of specific TFs selected
for their binding to the CD34 promoter, their involvement
in NO signaling in various systems, and their importance
in the hematopoietic system was examined in NO-treated
HSCs from juvenile and adult mice. Yy1, a multifunctional
polycomb group (PcG) transcription factor, has been
shown to mark phenotypically defined and functional LT-
HSCs and is also known to interfere with the commitment
process [30]. Consistent with these reports, Yy1 was found
to be significantly upregulated by NO in juvenile HSCs,
but not in adult HSCs. The regulation of Cd34 transcrip-
tion requires Sp1 [33]. We found that NO upregulated
Sp1 in both types of HSCs, but in juvenile HSCs the levels
of Sp1 were significantly higher. However, the level of
Cd34 in NO-treated juvenile HSCs was significantly lower
as compared to that in NO-treated adult HSCs. TF-bind
software-based analysis showed that Yy1 binds to the
Cd34 promoter, but its role in the regulation of Cd34 has
not been elucidated. YY1 is a ubiquitously distributed
transcription factor that is involved in repressing and acti-
vating a diverse number of promoters. It would be inter-
esting to determine whether it negatively regulates CD34
expression, thereby countering the positive regulatory ef-
fects of Sp1 on Cd34 in juvenile cells. Yet another TF that
was strongly upregulated by NO in juvenile HSCs was
Chop1. It is a basic leucine-zipper protein induced by a
variety of stimuli, including NO [52], that evokes cellular
stress responses. On the other hand, deletion of its hom-
ologous TF, C/EBP, has been shown to affect self-renewal
of HSCs [31]. It is thus possible that, in the juvenile HSCs,
Chop1 acts as a self-renewal factor and boosts the engraft-
ment ability of the HSCs. Consistent with previous reports
showing Runx-1 as a marker for long-term engrafting
HSCs [32], we found that Runx1 levels in NO-treated ju-
venile HSCs were significantly higher as compared to their
adult counterparts. Thus, high levels of Yy1, Chop1, and
Runx1, coupled with a comparatively lower level of Cd34,
may have resulted in the self-renewal and increased func-
tionality of juvenile HSCs. Our findings emphasize the
age-specific influences of NO in filling an important gap
in the existing knowledge about its role in hematopoiesis.
The surface expression of CXCR4 on HSCs plays an
important role in their homing, engraftment, and reten-
tion in the bone marrow of recipients [53]. NO has been
shown to enhance CXCR4 expression in human CD34+
HSCs collected from adult (BM and mobilized PB) as
well as neonatal sources (CB). Taking into consideration
the differences in engraftment shown by NO-treated
juvenile and adult HSCs, a possibility exists that this
may have been due to age-dependent effects of NO on
CXCR4 expression in murine HSCs. However, we found
that the treatment of juvenile as well as adult murine
HSCs with NO resulted in a strong upregulation of
CXCR4 on their surface, ruling out the possibility that
the differential effect of NO on their transplantation
ability could be related to differential effects on CXCR4
surface expression. Treatment of murine HSCs with
SNP has been shown to abrogate PGE2-mediated upreg-
ulation of CXCR4 [10]. However, we found that SNP in-
creases CXCR4 in both adult and juvenile HSCs. It is
possible that a combined presence of SNP and PGE2
negatively regulates CXCR4. Our data showing compro-
mised engraftment of SNP-treated adult HSCs in spite
of elevated CXCR4 expression suggest that a mere up-
regulation of CXCR4 surface expression cannot be taken
as a reliable indicator of engraftment ability of the HSCs.
Our data could have relevance in clinical transplantation.
Use of pharmacological compounds to enhance homing
and engraftment of HSCs has been widely attempted for
clinical transplantation. Such manipulation becomes im-
portant when the HSCs are either fewer in numbers (fetal
liver, CB) or possess compromised quality (aged donors).
Our murine data, taken together with the preliminary data
generated with CB and MBPL cells, show that NO exerts
age-dependent effects on HSC functionality.
In a wider perspective, our data point towards a possi-
bility that several other pharmacological reagents may also
have such contrasting effects on the functionality of HSCs
from developmentally distinct sources, and therefore HSC
age may be considered as an important parameter while
screening various compounds for their potential use in
HSC manipulation.
Conclusions
This study demonstrates novel age-dependent contrast-
ing effects of NO on HSC functionality and suggests
that HSC age may be an important parameter for
screening of various compounds for their use in ma-
nipulation of HSCs.
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Additional files
Additional file 1: Table S1. Antibodies. Table S2. List of gene-specific
primer sequence used for qRT-PCR analyses. Table S3. Sequence of
siRNA primers used for in vitro siRNA synthesis. (DOCX 20 kb)
Additional file 2: Figure S5. Treatment of adult HSCs with NO donor
reduces their engraftment ability. The donor cell chimerism in the PB of
recipients at 4 weeks (a) and 16 weeks (b) is depicted. (c, d) Lineage
commitment in regenerated hematopoietic cells in the PB of recipients at 4
and 16 weeks post-transplant is illustrated. After 16 weeks post-transplant
the mice were sacrificed and their BM cells were analyzed for percentage
engraftment by the donor cells. Percentage engraftment of total donor cells
(e) and percentage LSK-CD34− LT-HSCs (f) in the recipients’ BM at 16 weeks
post-transplant is illustrated. *p ≤ 0.05, ***p ≤ 0.001. Also see Fig. 7.
(TIF 761 kb)
Additional file 3: Figure S1. Fold-change in the number (a) and the
frequency (c) of various cells formed in the cultures treated or not with
200 μM SNP for 3 days is illustrated. Data represent means ± SEM of three
independent experiments performed. (b) Flow panel illustrates the gating
strategy used for flow cytometry analyses of HSC subpopulations. (d)
Graph depicts the ratio of LSK-CD34+ HSCs to LSK-CD34− HSCs in the
starting population and in the cells generated after 3 days of incubation
with or without the addition of 200 μM SNP. (e) Flow panel illustrates the
gating strategy used for EdU labeling experiment. ***p ≤ 0.001. Also see
Fig. 1. (TIF 4360 kb)
Additional file 4: Figure S2. SNP also increases surface expression and
mRNA levels of CD34 in LSK-CD34+ cells. Sort-purified LSK-CD34+ cells
were treated with various concentrations of SNP for 12 h and the cells
were analyzed on a flow cytometer. The frequency of LSK-CD34+ HSCs
formed in the cultures (a) and the MFI of CD34 fluorescence (b, c) is
shown. (d) Sort-purified LSK-CD34+ cells were treated with 200 μM SNP
for 12 h, and were subjected to qRT-PCR analyses. Relative expression of
Cd34-specific mRNA expression is graphically illustrated. *p ≤ 0.05,
**p ≤ 0.01. Also see Fig. 2. (TIF 1397 kb)
Additional file 5: Figure S3. Effects of NO donors on the membrane
expression of CD34. Sort-purified LSK-CD34− cells were treated with
various concentrations of SIN-1 and NOC-18 for 12 h. The increase in the
frequency of LSK-CD34+ cells formed and MFI of CD34 fluorescence in the
cells treated with SIN (a, b) and NOC-18 (c, d) are illustrated. ***p ≤ 0.001.
Also see Fig. 3. (e, f) Expression of Vegf-a-specific mRNA in BMSCs directly
treated with 100 μM 8-Cl-cGMP and BMSCs treated with 100 μM SNP in the
presence of 100 μM Rp-cGMP is depicted. The data show that 8-Cl-cGMP
significantly increased the Vegf-a expression in the BMSCs (e). Similarly,
SNP-mediated increase in Vegf-a expression was significantly inhibited by
Rp-cGMP (f). These data show that both chemicals exhibit desired activity.
*p≤ 0.05, **p≤ 0.01, ***p≤ 0.001. Also see Fig. 5. (TIF 512 kb)
Additional file 6: Figure S4. Treatment of adult HSCs with NO donor
does not induce lineage bias in regenerated blood cells. Lin− cells from
adult mice (10–12 weeks; CD45.1)) were treated with 200 μM SNP for
3 days and were infused into irradiated recipients (8–10 weeks; CD45.2).
Six mice were used per group. Donor cell chimerism was determined by
flow cytometry of recipients’ PB. (a) Experimental scheme is illustrated.
(b) Gating strategy used to analyze donor cell chimerism in the PB of
recipient mice. (c, d) Lineage commitment in regenerated hematopoietic
cells in the PB of recipients at 4 and 16 weeks post-transplant is illustrated.
Also see Fig. 7. (TIF 2833 kb)
Additional file 7: Figure S6. NO upregulates Cxcr4 expression in
murine HSCs. (a) Cxcr4-specific mRNA expression and (b) MFI of CXCR4
surface expression in SNP-treated juvenile and adult HSCs is graphically
illustrated. NO increases myeloid commitment of adult HSCs. (c) Gating
strategy applied for flow analysis of common myeloid progenitors (CMP)
and common lymphoid progenitors (CLP) is illustrated. (d) Frequencies of
CMP and CLP formed in SNP-treated adult and juvenile Lin− cells are
graphically represented. Comparative transcription factor analyses of
juvenile and adult HSCs treated with SNP. Sort-purified LSK-CD34− cells
from juvenile mice (6–8 weeks) and adult mice (10–12 weeks) were
treated with 200 μM SNP for 12 h and subjected to qRT-PCR analysis.
(e) Comparative gene expression of various transcription factors in the
treated cells is shown (N = 3). *p ≤ 0.05, **p ≤ 0.01, ***p ≤ 0.001, comparison
between control and SNP-treated sets; ###p ≤0.001, comparison between
SNP-treated juvenile versus SNP-treated adult HSCs. NS not significant. Also
see Fig. 7. (TIF 2406 kb)
Additional file 8: Figure S7. NO exerts age-specific contrasting effects
on human HSCs. (a) Gating strategy applied for human CD45+34+38−
HSCs is illustrated. (b) SNP-mediated increase in CD34-specific mRNA and
(c) frequency of CD34+38− HSCs in gated CD45+ population in SNP-
treated CB and MBPL cells are graphically represented. (d) Fold-change in
absolute numbers of CD45+34+38− HSCs generated in cultures over input
CD45+34+38− HSC population is depicted. N = 3. *p ≤ 0.05, **p ≤ 0.01,
***p ≤ 0.001. (TIF 1949 kb)
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